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Figure: Stoichiometric calibration curve. The HU shift for the 
dosimeter needed for a correct SPR estimation based on the 
curve is indicated with a red arrow. 
Conclusion: The stoichiometric method overestimates the 
measured SPR by 13%. Using DE this error is reduced, to an 
overestimation of 3%. If the stoichiometric method is used for 
the 3D dosimeter its HU must be corrected in the treatment 
planning system.  
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Purpose: Hypothalamic-pituitary axis (HPA) dysfunction is a 
dose-dependent sequela of brain irradiation. Meta-analysis of 
studies on non-pituitary central nervous system tumours 
performed by Appelman-Dijkstra et al. [The Journal of 
Clinical Endocrinology & Metabolism, 8, 2330 (2011)] found 
estimated doses of 25-97 Gy to the HPA and 0.54 prevalence 
of pituitary deficiency. However, no included study reported 
the site-specific doses to the hypothalamus or pituitary. As 
the hypothalamus is thought to be more radiosensitive than 
the pituitary, greater understanding of the structural 
organization and normal tissue tolerances of these two 
structures is necessary to better describe the relationship 
between HPA radiation dose and secondary insufficiency. The 
purpose of this study is to characterize the radiation dose to 
the HPA in adults treated for non-pituitary brain tumours. 
Materials/Methods: Twelve patients, 3 males and 9 females, 
have been enrolled in our prospective VoxTox study that will 
continue to recruit until 2017. Primary diagnoses included 
meningioma (7), pineal tumor (3), and glioma (2). Patients 
were treated with TomoTherapy® and received 50-60 Gy to 
the tumour bed in 30 fractions. Digital Imaging and 
Communications in Medicine radiotherapy data, including 
dose cubes, contours and planning imaging, were retrieved 
from TomoTherapy® archives using an in-house software and 
imported into ProSoma virtual simulation software. Quality 
assurance of hypothalamus and pituitary contours was 
performed. Parametrisation of dosimetric data from planning 
computed tomography scans was used to determine mean 
radiation doses to the hypothalamus and pituitary separately. 
Dose volume histogram data were exported to Matlab®. 
Equivalent uniform doses (EUDs) for a parallel structure (a=1) 
and serial structure (a=20) were calculated utilizing a freely 
available program and normal tissue tolerance parameters 
for the lung and spinal cord, respectively. 
Results: The mean radiation doses to the hypothalamus and 
pituitary were 35 Gy and 34 Gy, respectively. Serial and 
parallel EUDs for each patient are presented in Figure 1. The 
mean EUDs for a=1 and a=20 were 30 Gy (range 14-52) and 33 
Gy (range 19-52), respectively, for the hypothalamus and 29 
(range 8-46) and 31 Gy (range 8-46), respectively, for the 
pituitary. The mean difference between serial and parallel 
EUD values was 3 Gy for both the hypothalamus and the 
pituitary. 
Conclusions: The organization of the hypothalamus and 
pituitary into serial or parallel structures may not be 
predictive of HPA response to radiation. Future studies are 
necessary to isolate the dose-volume effects of these two 
organs.  
 
 
 
Figure 1. EUD doses to the hypothalamus (blue) and pituitary 
(red) are presented for parallel (circle) and serial (triangle) 
structures for each patient. 
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Purpose:  In NSCLC radiotherapy, personalized radiation 
treatment is intended to deliver an appropriate amount of 
dose to control the tumor while reducing radiation-induced 
toxicities such as radiation pneumonitis, esophagitis, carditis.  
The outcomes of radiation treatment may depend on 
radiation dose and patients’ physical, clinical, biological and 
genomic characteristics before and during the course of 
radiotherapy.  We intend to find hierarchical biophysical 
relationships influencing the observed outcomes from 
retrospective data and develop practical Bayesian Networks 
(BN) for adaptive radiotherapy of the NSCLC. 
Materials/methods:  Our study includes 79 NSCLC patients 
treated on prospective protocols under IRB approval.  In 
addition to dosimetric information, each patient had 179 
features from five categories including clinical factors (10) 
(e.g., age, KPS), cytokines before (30) and during (30) the 
treatment course, microRNAs (49), and single-nucleotide 
polymorphisms (SNPs) (60).  A large-scale Markov blanket 
based on the HITON algorithm is employed for selecting 
relevant biophysical predictors of outcomes.  The 
corresponding BN structure is obtained using the hill-climbing 
algorithm implemented in the R programming environment.  
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The BN is guarded against overfitting using k-fold cross 
validation. 
Results:  BNs representing the biophysical relationships 
before and during the course of radiotherapy behind the 
radiation outcomes are identified and designated as 
“biophysical BNs’’.  They can be adjusted to “practical BNs” 
for adaptive therapy purposes, with a possibility of minor 
compromise of estimated prediction power.  Given a 
patient’s pretreatment data, an appropriate treatment plan 
can be chosen from a practical BN to control the tumor and 
keep the radiation toxicities under a certain level.  When the 
patient’s during treatment information is available, the 
planned dose can be adjusted in the BN according to his/her 
responses, to better control tumor without increasing the 
chance of the complication.  Cross validation is employed to 
measure the prediction power of the BNs.  For example, 
while the performance of a pretreatment BN to predict 
radiation pneumonitis ≥G2 is 0.80 with 95% CI: 0.69-0.90 
based on 2000 stratified bootstrap replicates, the AUC of the 
BN with patients’ responses during radiotherapy can reach 
0.84 (95% CI: 0.78-0.92). 
Conclusions:  We developed clinically practical systems to 
predict the radiation outcomes in NSCLC patients before and 
during the course of radiation treatment based on 
retrospective data.  The prediction performance of the BN 
improves by incorporating during treatment information.  Our 
approach can handle high dimensional predictors and can be 
an important component of decision support for personalized 
adaptive radiation treatment.  However, it still needs to be 
validated in external independent data. 
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Purpose: The interest in particle therapy is growing 
worldwide with clinical applications focused on protons and 
carbon ion beams. Moreover, at the Heidelberg Ion Beam 
Therapy Center, helium and oxygen ions are available for 
research purposes with an active scanning beam delivery 
system. While most of the planning studies comparing these 
four ions are based on non-experimentally validated 
calculations, this work is focused on the basic experimental 
dosimetric characterizations and comparisons of these ions at 
the same facility. 
Material/methods: Laterally integrated depth-dose 
distributions of pencil-like beams, for 10 different energies in 
the therapeutic range have been experimentally studied, 
with a range in water similar for every ion. Several 
parameters were evaluated, as the range, the entrance-to-
peak ratio, the width of the Bragg peak, the distal fall-off 
and the tail-to-peak ratio, and this with and without ripple 
filter (used to broaden the pristine peaks). The 
measurements were performed using a water column, by 
delivering quasi-monoenergetic pencil-like beams on the 
central axis. 
The lateral dose profiles of these ions, at low, middle and 
high beam energy, were investigated at different depths in 
water (without ripple filter). Along with the acquisition of 
these data, a double-Gaussian parametrization was 
performed and the evolution of its components along the 
depth in water was examined. The measurements have been 
done in a water tank coupled with 24 motor-driven PinPoint 
ionization chambers by delivering a vertically scanned beam. 
Results: For the depth-dose characterization, the evolution 
of the investigated parameters presents a different behavior 
depending on the energy, the ion and the presence or not of 
ripple filter. Helium ions present interesting intermediate 
characteristics with a distal fall-off smaller than protons and 
a reduce fragmentation tail compare to heavier ions. These 
characteristics suggest different advantages and/or 
drawbacks for the ions depending on the situation, and a 
compromise among them has to be found for later treatment 
planning. 
The lateral profiles and their double Gaussian 
parametrizations present net advantages of the heavy ions 
compared to protons with intermediate results for helium 
ions. 
Conclusions: Our experimental results indicate that helium 
ions could be a good candidate for further particle therapy 
improvements, with intermediate properties between the 
clinically used proton and carbon ions. The main features are 
the favorable physical characteristics, especially a smaller 
lateral scattering than protons and a very low tail-to-peak 
ratio compared to carbon ions. This study was used to create 
the first helium ions database, allowing biological 
experiments needed to ensure proper treatment planning and 
future fair comparisons for planning studies between the 
ions. 
We acknowledge funding from DFG (KFO 
Schwerionentherapie 214). 
 
 
Figure 1: Measured Bragg peaks (symbols) and their 
interpolation (lines), normalized to maximum and to the 
peak position, for a range in water of ~15cm.  
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Over the last decades, survival rates for most cancer patients 
have only marginally increased. One reason for the limited 
decline in this death rate is the lack of effective treatment 
strategies especially in advanced cancers. In oncology 
research, drug development processes have proven to be very 
inefficient and this has been partly attributed to the lack of 
adequate preclinical testing modalities. Research in our lab is 
specifically focused on lung and brain cancer, both amongst 
the most malignant and difficult to treat neoplasms with very 
poor overall 5-year survival rates. In advanced disease most 
patients receive chemo- and radiotherapy (CRT), but 
response to treatment is generally poor with only minimal 
effects on survival while decreasing the patients’ quality of 
life. Tumors almost invariably recur or are intrinsically 
resistant to chemotherapy. Improvement of tumor control at 
primary and distant locations is compulsory. The goal of our 
research is to identify novel treatment combinations that will 
result in improved outcome for patients with advanced lung 
or brain malignancies. 
